1827 / 1851
Toxicity of concurrent SRT and
antibody therapy
Anti-VEGF (bevacizumab)
additional risk of concurrent cranial SRT and bevacizumab is small
(neurological toxicity)
possibly protective to the development of radionecrosis.
combination of bevacizumab and extra-cranial SBRT: scarce data
concurrent abdominal SRT and bevacizumab should be practised
with caution.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37